Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941
In development [GID-TA10832] Expected publication date: TBC
Search results
480 results
-
-
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
In development [GID-TA10948] Expected publication date: TBC
-
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]
In development [GID-TA10785] Expected publication date: 16 November 2022
-
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant [ID3969]
In development [GID-TA10852] Expected publication date: TBC
-
Baricitinib for treating severe alopecia areata ID3979
In development [GID-TA10941] Expected publication date: TBC
-
Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]
In development [GID-TA10983] Expected publication date: TBC
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 20 July 2022
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
In development [GID-TA10691] Expected publication date: 13 July 2022
-
Brolucizumab for treating diabetic macular oedema [ID3902]
In development [GID-TA10794] Expected publication date: 16 November 2022
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID3860]
In development [GID-TA10746] Expected publication date: 01 March 2023
-
Foslevodopa-foscarbidopa for treating Parkinson's disease with motor symptoms [ID3876]
In development [GID-TA10772] Expected publication date: 03 May 2023
-
Tirzepatide for treating type 2 diabetes ID3938
In development [GID-TA10835] Expected publication date: TBC
-
Risankizumab for previously treated moderately to severely active Crohn's disease [ID3986]
In development [GID-TA10884] Expected publication date: 08 March 2023
-
Avalglucosidase alfa for treating Pompe disease [ID3737]
In development [GID-TA10876] Expected publication date: 17 August 2022
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: 19 January 2023
-
Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]
In development [GID-TA10645] Expected publication date: 10 August 2022
-
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]
In development [GID-TA10806] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
In development [GID-TA10652] Expected publication date: 11 January 2023
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: TBC
-
Teduglutide for treating short bowel syndrome [ID3937]
In development [GID-TA10842] Expected publication date: 29 June 2022
-
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
In development [GID-TA10845] Expected publication date: TBC
-
Tezepelumab for treating severe asthma [ID3910]
In development [GID-TA10796] Expected publication date: TBC
-
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma [ID1465]
In development [GID-TA10352] Expected publication date: TBC
-
Upadacitinib for previously treated moderately to severely active Crohn's disease [ID4027]
In development [GID-TA10997] Expected publication date: TBC
-
Pralsetinib for RET fusion-positive advanced non-small-cell lung cancer [ID3875]
In development [GID-TA10770] Expected publication date: 23 June 2022
-
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: TBC
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
In development [GID-TA10812] Expected publication date: 25 January 2023
-
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (CDF review of TA559) [ID3980]
In development [GID-TA10951] Expected publication date: 25 January 2023
-
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]
In development [GID-TA10738] Expected publication date: TBC
-
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
In development [GID-TA10105] Expected publication date: TBC
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: 22 June 2022
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
In development [GID-TA10732] Expected publication date: 21 September 2022
-
Therapeutics for people with COVID-19 [ID4038]
In development [GID-TA10936] Expected publication date: TBC
-
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]
In development [GID-TA10825] Expected publication date: 29 July 2022
-
Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]
In development [GID-TA10975] Expected publication date: 01 March 2023
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: TBC
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 12 October 2022
-
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]
In development [GID-TA10824] Expected publication date: 01 March 2023
-
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: TBC
-
Ravulizumab for treating refractory antibody positive generalised myasthenia gravis [ID4019]
In development [GID-TA10987] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
In development [GID-TA10505] Expected publication date: 01 March 2023
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
In development [GID-TA10781] Expected publication date: TBC